Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 13/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 10/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | FLT4 | P35916 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881759 | 0.96 | PTGS2 (0.46) | MAPTPTGS2MCL1BCL2L1HDAC3 | |
| SCHEMBL5881771 | 0.93 | FLT1 (0.51) | MAPTPTGS2MCL1BCL2L1HDAC3 | |
| SCHEMBL5881720 | 0.92 | PTGS2 (0.42) | MAPTPTGS2MCL1BCL2L1HDAC3 | |
| SCHEMBL5882177 | 0.91 | FLT1 (0.47) | MAPTPTGS2MCL1BCL2L1HDAC3 | |
| SCHEMBL6318645 | 0.88 | MAPT (0.45) | MAPTPTGS2MCL1BCL2L1HDAC3 | |
| SCHEMBL5881987 | 0.87 | MAPT (0.42) | MAPTPTGS2MCL1HDAC3HDAC4 | |
| SCHEMBL6318323 | 0.87 | MAPT (0.43) | MAPTPTGS2MCL1BCL2L1HDAC3 | |
| SCHEMBL5881755 | 0.85 | PTPN1 (0.48) | MAPTPTGS2MCL1BCL2L1 | |
| SCHEMBL5882503 | 0.85 | FLT1 (0.50) | MAPTPTGS2FLT1FLT4KDR | |
| SCHEMBL5881662 | 0.85 | PTPN5 (0.53) | MAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1132087-A1 | REMEDIES FOR POLYCYSTIC OVARY SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | MAPT 4038/4885PTGS2 230/4885MCL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.